Zidovudine
- Generic Name
- Zidovudine
- Brand Names
- Combivir, Retrovir, Trizivir
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N5O4
- CAS Number
- 30516-87-1
- Unique Ingredient Identifier
- 4B9XT59T7S
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
- Indication
Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Perinatal HIV transmission
- Associated Therapies
- -
A Randomized, Comparative Trial of Zidovudine (AZT) Versus 2',3'-Didehydro-3'-Deoxythymidine (Stavudine; d4T) in Children With HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 230
- Registration Number
- NCT00000789
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇺🇸The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia, Pennsylvania, United States
🇺🇸St. Christopher's Hosp. for Children, Philadelphia, Pennsylvania, United States
A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 1750
- Registration Number
- NCT00000841
- Locations
- 🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸Emory Univ, Atlanta, Georgia, United States
Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 120
- Registration Number
- NCT00000810
- Locations
- 🇺🇸
Howard University Hosp., Div. of Infectious Diseases, ACTU, Washington, District of Columbia, United States
🇺🇸Stanford CRS, Stanford, California, United States
🇺🇸SUNY - Buffalo, Erie County Medical Ctr., Buffalo, New York, United States
A Study of Dideoxycytidine Plus Zidovudine (AZT) in HIV-Infected Children Who Have Taken AZT
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 180
- Registration Number
- NCT00001032
- Locations
- 🇺🇸
The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia, Pennsylvania, United States
🇺🇸Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States
🇺🇸Chicago Children's CRS, Chicago, Illinois, United States
Evaluation of the Interaction Between Acetaminophen and Zidovudine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 10
- Registration Number
- NCT00000731
- Locations
- 🇺🇸
Univ of Pittsburgh Med School, Pittsburgh, Pennsylvania, United States
A Trial of Alternating 2',3'-Dideoxycytidine and Zidovudine in the Treatment of Patients With Advanced HIV Disease
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 96
- Registration Number
- NCT00000719
- Locations
- 🇺🇸
Univ. of Miami AIDS CRS, Miami, Florida, United States
🇺🇸University of Minnesota, ACTU, Minneapolis, Minnesota, United States
🇺🇸USC CRS, Los Angeles, California, United States
Evaluation of the Interaction Between Low Dose Sulfamethoxazole-Trimethoprim and Zidovudine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 10
- Registration Number
- NCT00000732
- Locations
- 🇺🇸
Univ of Pittsburgh Med School, Pittsburgh, Pennsylvania, United States
A Study of Didanosine Use Alone or in Combination With Zidovudine in Infants Exposed to or Infected With HIV
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 180
- Registration Number
- NCT00001049
- Locations
- 🇺🇸
Children's Hosp of Washington DC, Washington, District of Columbia, United States
🇺🇸Univ of Illinois College of Medicine / Pediatrics, Chicago, Illinois, United States
🇺🇸Chicago Children's Memorial Hosp, Chicago, Illinois, United States
A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 26
- Registration Number
- NCT00000878
- Locations
- 🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
🇺🇸Univ of Chicago Children's Hosp, Chicago, Illinois, United States
🇺🇸Children's Hosp of Boston, Boston, Massachusetts, United States
A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 200
- Registration Number
- NCT00000870
- Locations
- 🇺🇸
The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States
🇺🇸Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States
🇺🇸Case CRS, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.